Press Release December 14, 2022

Larkspur Health Acquisition Corp. Combines with ZyVersa Therapeutics

Alston & Bird client Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company, has completed its business combination with ZyVersa Therapeutics Inc., a clinical stage specialty biopharmaceutical company, in a transaction valued at $108.92 million.
Representing Larkspur was an Alston & Bird team led by partners Matt Mamak and Stuart Rogers, senior associate Robyn Downing, and associates Misbah Mohiuddin, Siena Cornacchini, and Steven Chen (Corporate & Business Transactions).
Media Contact
Alex Wolfe
Communications Director

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.